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Abstract: The diversity of actinomycetes associated with marine sponges collected off 
Fsar Reef (Saudi Arabia) was investigated in the present study. Forty-seven actinomycetes 
were cultivated and phylogenetically identified based on 16S rRNA gene sequencing and 
were assigned to 10 different actinomycete genera. Eight putatively novel species 
belonging to genera Kocuria, Mycobacterium, Nocardia, and Rhodococcus were identified 
based on sequence similarity values below 98.2% to other 16S rRNA gene sequences 
available in the NCBI database. PCR-based screening for biosynthetic genes including type I 
and type II polyketide synthases (PKS-I, PKS-II) as well as nonribosomal peptide 
synthetases (NRPS) showed that 20 actinomycete isolates encoded each at least one type of 
biosynthetic gene. The organic extracts of nine isolates displayed bioactivity against at 
least one of the test pathogens, which were Gram-positive and Gram-negative bacteria, 
fungi, human parasites, as well as in a West Nile Virus protease enzymatic assay. These 
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results emphasize that marine sponges are a prolific resource for novel bioactive 
actinomycetes with potential for drug discovery. 
Keywords: PKS I; PKS II; NRPS; Red Sea; sponges; actinomycetes; bioactivity 
 
1. Introduction 
Sponges (Porifera) are the oldest, evolutionarily ancient multicellular phylum with a fossil record 
dating back to Precambrian times [1]. The phylum Porifera consists of three major classes, 
Hexactinellida (glass sponges), Calcarea (calcareous sponges) and Demospongiae (demosponges), 
with the last group representing 85% of all living sponges [2]. Sponges populate tropical reefs in great 
abundance but also the polar latitudes as well as fresh water lakes and rivers [3,4]. Sponges have 
developed intimate contact with diverse microorganisms such as viruses, bacteria, archaea, fungi, 
protozoa, and single-celled algae and the nature of the sponge-microbe interaction is manifold [5]. The 
microbial distribution in most sponges follows a general pattern with the photosynthetically active 
microorganisms such as Cyanobacteria located in the outer light exposed layers while heterotrophic 
and possibly autotrophic bacteria inhabiting the inner core [6]. So far, at least 32 bacterial phyla  
and candidate phyla were described from marine sponges by both cultivation-dependent and 
cultivation-independent techniques; with the most common phyla being Acidobacteria, Actinobacteria, 
Chloroflexi, Cyanobacteria, Gemmatimonadetes, Nitrospira, Planctomycetes, Proteobacteria, (Alpha, 
Delta, Gamma subclasses) and Spirochaetes [1,3]. 
The phylum Actinobacteria represents one of the largest taxonomic units among the 18 major 
lineages currently recognized within the domain bacteria [7]. The subclass Actinobacteridae includes 
the order Actinomycetales, members of which are commonly referred to as actinomycetes. These are 
Gram positive bacteria characterized by their ability to form branching hyphae at some stages of their 
development [8]. Within the order Actinomycetales, approximately 49 families have been recognized 
with the most common ones being Actinomycetaceae, Actinoplanaceae, Dermatophilaceae, Frankiaceae, 
Mycobacteriaceae, Micromonosporaceae, Nocardiaceae, and Streptomycetaceae, comprising 
altogether 147 genera [9,10]. Actinobacteria are widespread in nature and have been recovered from a 
wide variety of terrestrial habitats, where they exist as saprophytes, symbionts or pathogens [11–13]. 
Actinomycetes have been cultivated from the marine environment including sea water [14], marine 
snow, and marine sediments [15]. Actinomycetes have also been cultivated from different marine 
invertebrates [16–18], with the majority being isolated from sponges [19,20]. Marine actinomycetes 
produced a multitude of novel lead compounds with medicinal and pharmaceutical applications. Figure 1 
shows the percentage distribution of compounds obtained from marine sponge-associated bacteria. 
Here, actinomycetes account for approximately half of the natural products (MarinLit database 2013 
(John Blunt, MarinLit, University of Canterbury, New Zealand) [21,22]), (Figure 1). Biological 
activities such as antibacterial, antifungal, antiparasitic, antimalarial, immunomodulatory,  
anti-inflammatory, antioxidant, and anticancer activities were reported from sponge-associated 
actinomycetes [23–26]. These bioactivities are represented by diverse leads of secondary metabolites 
including polyketides, alkaloids, peptides, and terpenes [24,25,27–30]. 
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Figure 1. Percentage distribution of compounds produced by sponge-associated bacteria 
(data collected from MarinLit 2013 and literature). 
 
Polyketide synthases (PKS) and nonribosomal peptide synthetases (NRPS) are multi-domain 
megasynthases that are involved in the biosynthesis of a large fraction of diverse microbial natural 
products known as polyketides and nonribosomal peptides, respectively [31]. These enzymes are 
widely distributed among the actinomycetes, cyanobacteria, myxobacteria, and fungi [32]. Structurally, 
both PKS and NRPS are complex polypeptides organized in a modular fashion for assembling 
carboxylic acid and amino acid building blocks into their final products [33]. Each PKS module 
encodes three basic domains including ketosynthase (KS), acyltransferase (AT), and acyl carrier 
protein (ACP), which are involved in the selection and condensation of the correct extender unit. 
Similarly, NRPS modules consist of condensation, adenylation, and thiolation domains for recognition 
and condensation of the starter substrate [31]. In this study, actinomycetes were cultivated from marine 
sponge species collected from the Red Sea. The obtained actinomycetes were phylogenetically 
characterized based on 16S rRNA gene sequencing and their genomic potential for natural products 
biosynthesis as well as their biological activities in an infection context are reported. 
2. Results and Discussion 
The Red Sea is one of the most biodiverse marine environments worldwide. It is characterized by 
high temperature (about 24 °C in spring and up to 35 °C in summer) and high salinity (ca. 40.0 psu), 
rendering this environment physically and chemically different from most other marine ecosystems [34]. 
About 240 demosponges have been formally recorded from the Red Sea so far and still many more 
await discovery [35]. Ngugi et al. reported a high bacterial diversity in the Red Sea in comparison to 
other tropical seas [36]. However, few studies have been carried out so far to investigate actinobacterial 
communities from Red Sea sponges. One such example is the study by Radwan et al. [37] who explored 
the microbial diversity of two Red Sea sponges, Hyrtios erectus and Amphimedon sp., using cultivation 
and cultivation-independent analyses. 
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2.1. Actinomycete Isolation and Phylogenetic Identification 
Twenty-five isolates were selected out of cultivated 47 isolates based on their characteristic colony 
morphology. The 16S rRNA genes as taxonomic markers were sequenced and sequences were blasted 
against the NCBI GenBank database. The results showed that the isolates belonged to 10 different 
genera representing six families (Dietziaceae, Micrococcaceae, Micromonosporaceae, Mycobacteriaceae, 
Nocardiaceae, Pseudonocardiaceae) and four suborders (Corynebacterineae, Micrococcineae, 
Micromonosporineae, Pseudonocardineae). Eight putatively new species were identified based on 
sequence similarities <98.2%, which belonged to the genera Kocuria, Mycobacterium, Nocardia and 
Rhodococcus (Table 1). From a taxonomic perspective, sequence similarities after BlAST analysis 
against type strains may even be lower. As one example, the isolate SA8 showed 96% sequence 
similarity to the closest type strain (Rhodococcus trifolii
T
). However, as type strains are not available 
for all obtained isolates, this taxonomically meaningful comparison remains restricted. 
Table 1. 16S rRNA gene taxonomic affiliation of cultivated strains. 
Isolate 
Code 
Isolation 
Medium 
Sponge Source 
Sequence 
Length (bp) 
Closest Relative by 
BLAST 
% Sequence 
Similarity 
SA1 M1 Amphimedon ochracea 1379 
Micrococcus sp. PN13 
(KF554087) 
99.4 
SA2 ISP2 Amphimedon aff. chloros 1435 
Micrococcus luteus 
strain DAG I 
(KC470045) 
99.7 
SA3 ISP2 Amphimedon aff. chloros 1360 
Micrococcus sp. X2Bc2 
(KF465977) 
99.5 
SA4 ISP2 Hyrtios erectus 1423 
Micromonospora sp. S6 
(HF674982) 
99.7 
SA5 OLIGO Chalinula sp. 1395 
Salinispora arenicola 
CNS-205 (NR_074612) 
99.9 
SA6 OLIGO Chalinula sp. 1372 
Salinispora arenicola 
strain SCSIOZ-SH19 
(KC747487) 
100.0 
* SA7 ISP2 Chalinula sp. 1338 
Nocardia sp. W9912 
(GU992878) 
98.2 
* SA8 ISP2 Chalinula sp. 1461 
Rhodococcus equi 
(AB738794)  
97.4 
* SA9 ISP2 Monanchora sp. 1378 
Rhodococcus sp. L-15 
(JN006270)  
97.9 
SA10 M1 Chalinula sp. 1397 
Micrococcus sp.  
PA-E028 (FJ233852) 
99.8 
* SA11 M1 Monanchora sp. 1416 
Mycobacterium sp. 
CNJ879 PL04 
(DQ448780) 
97.6 
* SA12 ISP2 Chalinula sp. 1374 
Rhodococcus sp. HL-3 
(JF734314) 
97.9 
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Table 1. Cont. 
* SA13 M1 Monanchora sp. 1419 
Mycobacterium sp. 
CNJ879 PL04 
(DQ448780) 
97.8 
* SA14 M1 Amphimedon ochracea 1341 
Kocuria sp. PN5 
(KF554079) 
97.5 
* SA15 M1 Amphimedon aff. chloros 1347 
Kocuria sp. SS263-23 
(JX429815) 
97.3 
SA16 M1 Amphimedon aff. chloros 1395 
Rothia terrae strain 
F77052 (HQ908743) 
99.7 
SA17 ISP2 Crella cyathophora 1401 
Micrococcus sp.  
X-48(JX997909) 
99.9 
SA18 M1 Amphimedon aff. chloros 1413 
Dietzia maris strain 
KMGL1309-AS3 
(KF740541) 
100.0 
SA19 OLIGO Chalinula sp. 1325 
Salinispora pacifica 
strain AMS365 
(HQ873949) 
99.9 
SA20 M1 Subera sp. 1330 
Salinispora arenicola 
strain SCSIOZ-SH19 
(KC747487) 
100.0 
SA21 ISP2 Subera sp. 1443 
Saccharomonospora 
azurea strain RR1 
(KC855265) 
99.2 
SA22 OLIGO Subera sp. 1337 
Salinispora pacifica 
strain S34 (JX007964) 
99.7 
SA23 ISP2 Amphimedon aff. chloros 1396 
Saccharomonospora 
sp. G2Z21 (JF806667) 
99.8 
SA24 M1 
Dactylospongia  
aff. elegans 
1494 
Kocuria palustris strain 
LJ27 (KF515677) 
99.1 
SA25 OLIGO Hyrtios erectus 1453 
Salinispora arenicola 
strain SCSIOZ-SH11 
(KC747479) 
99.9 
* Putatively new species. 
The recoverability of actinomycetes varied between different sponge sources; for example, 
Amphimedon aff. chloros yielded 17 actinomycetes (six genera), while A. ochracea yielded only four 
isolates from three different genera. These numbers compare to the recovery of four actinomycetes 
(two genera) from Amphimedon sp. from Ras Mohamed (Egypt) [17], 16 actinomycete (four genera) from 
Amphimedon sp. collected from Hurghada (Egypt) [37], and zero actinomycetes from A. complanata 
collected from Puerto Rico [38]. Similarly, while Radwan et al. [37] isolated 18 actinomycetes  
(four genera) from Hyrtios erectos, we obtained only three actinomycetes from this sponge species, 
albeit collected at a different location. Contrary to previous reports [39], we did not succeed in isolating 
actinomycetes from Xestospongia aff. testudinaria. This sporadic isolation of actinomycetes could be 
explained by environmental factors that would influence the diversity, abundance and recoverability of 
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actinomycetes from sponges. The observed differences also highlight the importance of using a wide 
range of media to increase the isolation efficiency of marine sponge-associated actinomycetes. 
M1, ISP2 and OLIGO media were chosen for actinomycete cultivation based on previous 
experience and literature reports [17,40]. M1 medium produced the highest number of actinobacterial 
colonies (25), followed by ISP2 (16), while only six isolates were recovered on OLIGO (Figure 2B). 
Zhang et al. demonstrated that the lack of free amino acids resulted in low recovery of  
marine actinobacteria [19]. Accordingly, peptone was added to M1 medium which resulted in both, a 
higher number of actinomycetes and recovery of more genera. Consistent with previous studies [38,41], 
the genera Rhodococcus, Micromonospora, and Nocardia were cultivated preferentially on ISP2, while  
Salinispora grew better on oligotrophic media [42,43]. 
The genus Micrococcus was represented by the highest number of isolates (14) which is likely due 
to their fast growing nature, rendering them easy to isolate. The second most abundant genus (7) was 
Salinispora which is frequently isolated from sea water, sediments, as well as sponges [43,44].  
The other genera belonged to Rhodococcus (6), Kocuria (5), Micromonospora (4), Dietzia (3), 
Saccharomonospora (3), Mycobacterium (2), Nocardia (2), and Rothia (1). 
Figure 2. Number of actinomycete isolates (A) per sponge species, (B) per isolation media. 
 
A maximum-likelihood tree was calculated for the 25 isolates with the nearest sequence relatives 
from a Blast run included (Figure 3). The Rhodococcus isolates sp. SA8, SA9 and SA12 formed a 
distinct cluster. The high similarity and high bootstrap value (100) along with a multifurcation in the 
tree suggests that the isolates represent the same species. The isolates SA11, SA13, SA14, and SA15 
form distinct clades in the genera Mycobacterium and Kocuria. Interestingly, isolate SA7 falls within 
the genus Nocardia and also shows the lowest level of similarity (98.2%). In this case, further 
phenotypic and genotypic characterization may be needed to validate the exact taxonomic position of 
this isolate which might be a novel species within the genus Nocardia. 
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Figure 3. Maximum-likelihood tree of the actinomycete isolates SA1-SA25 (in bold) and 
their closest phylogenetic relatives based on the 16S rRNA gene marker. Brackets indicate 
genus-level assignment. Bootstrap values (1000 resamples) are given in percent at the 
nodes of the tree (greater than 50). The arrow points to the outgroup (Escherichia coli 
KTCT 2441
T
). 
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2.2. PCR-Screening for PKS and NRPS Domains 
Twenty-five actinomycetes were tested using degenerate PCR primers for the presence of 
polyketide synthases Type I and II (PKS-I and PKS-II) and nonribosomal peptide synthetases (NRPS). 
At least one type of biosynthetic gene sequence was recovered from 20 actinomycete isolates (80%), 
(Table 2). All three types of biosynthetic genes were found in the actinomycetes (7) belonging to 
genera Micromonospora and Salinispora. This is unsurprising since Micromonospora and Salinispora 
are well known for their natural product diversity encompassing different metabolite classes [25,27,45]. 
NRPS biosynthetic genes were identified in 19 isolates (76%), while PKS-I genes were detected in 
12 strains (48%), and PKS-II genes in eight strains (32%). NRPS and PKS sequence diversity have 
been reported in marine actinomycetes isolated from different marine environments including marine 
caves, marine sediments, and marine sponges, where these sequences were detected in up to 90% of 
the tested strains [46,47]. 
Table 2. NRPS and PKS results of cultivated strains. 
Isolate 
Code 
Closest Relative by BLASTX (Sequence Length bp, % Sequence Similarity) 
NRPS PKS I PKS II 
SA1 Amino acid adenylation 
domain-containing protein 
[Micrococcus luteus 
(CP001628)] (347, 51) 
- - 
SA2 Non-ribosomal peptide 
synthetase [Micrococcus 
luteus (EFD52022)] (417, 56) 
- - 
SA3 Amino acid adenylation 
domain-containing protein 
[Micrococcus luteus 
(CP001628)] (511, 62) 
- - 
SA4 Amino acid adenylation 
domain-containing protein 
[Micromonospora aurantiaca 
(WP_013285021)] (501, 79) 
Polyketide synthase 
[Micromonospora sp. CNB394 
(WP_018787726)] (473, 67) 
Type II PKS ketosynthase, 
partial [Micromonospora sp. 
SCSIO11524 (AHB18630)] 
(541, 63) 
SA5 Amino acid adenylation 
domain-containing protein 
[Salinispora arenicola 
(WP_012184557)] (521, 72) 
Polyketide synthase 
[Salinispora arenicola 
(WP_018795623)] (541, 64) 
Beta-ACP synthase, partial 
[Salinispora arenicola 
(WP_020608853)] (573, 70) 
SA6 Amino acid adenylation 
domain-containing protein 
[Salinispora arenicola 
(YP_001535283)] (513, 77) 
Polyketide synthase 
[Salinispora arenicola 
(WP_018795623)] (516, 71) 
KAS II  
[Salinispora arenicola 
(WP_020608853)] (581, 67) 
* SA7 - - Polyketide synthase 
[Nocardia nova SH22a 
(AHH16328)] (614, 85) 
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* SA8 Non-ribosomal peptide 
synthetase [Rhodococcus equi 
(CBH48735)] (570, 69) 
Putative polyketide synthase 
[Rhodococcus equi 
(WP_022593366)] (518, 65) 
- 
* SA9 Non-ribosomal peptide 
synthetase, partial 
[Rhodococcus qingshengii 
(WP_007730195)] (609, 68) 
Putative polyketide synthase 
[Rhodococcus opacus B4 
(BAH55256)] (428, 75) 
- 
SA10 - - - 
* SA11 - - - 
* SA12 Non-ribosomal peptide 
synthetase [Rhodococcus 
opacus (WP_005253470)] 
(622, 58) 
Putative polyketide synthase 
[Rhodococcus opacus 
(BAH55256)] (428, 75) 
- 
* SA13 - - - 
* SA14 Non-ribosomal peptide 
synthetase [Kocuria 
rhizophila (BAG29492)] 
(532, 74) 
- - 
*SA15 Non-ribosomal peptide 
synthetase [Kocuria 
rhizophila (BAG29492)] 
(462, 68) 
- - 
SA16 - - - 
SA17 Non-ribosomal peptide 
synthetase [Micrococcus 
luteus (EFD52022) (423, 66) 
- - 
SA18 - - - 
SA19 Adenylation domain of 
nonribosomal peptide 
synthetase [Salinispora 
pacifica (WP_018724218)] 
(465, 58) 
Polyketide synthase 
[Salinispora pacifica 
(WP_018824659)] (421, 59) 
Beta-ACP synthase 
[Salinispora pacifica 
(WP_018720155)] (541, 61) 
SA20 Amino acid adenylation 
domain-containing protein 
[Salinispora arenicola 
(WP_012184557)] (465, 58) 
Polyketide synthase 
[Salinispora arenicola 
(WP_019032802)] (506, 61) 
KAS II [Salinispora 
arenicola (WP_020608853)] 
(529, 57) 
SA21 Nonribosomal peptide 
synthetase 
[Saccharopolyspora spinosa 
(WP_010314019)] (665, 74) 
Polyketide synthase 
[Saccharopolyspora spinosa 
(WP_010311945)] (565, 69) 
- 
SA22 Amino acid adenylation 
domain of nonribosomal 
peptide synthetase 
[Salinispora pacifica 
(WP_018724218)] (476, 59) 
Polyketide synthase 
[Salinispora pacifica 
(WP_018824659)] (501, 63) 
Beta-ACP synthase 
[Salinispora pacifica 
(WP_018823591)] (531, 71) 
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SA23 Amino acid adenylation 
domain-containing protein 
[Saccharopolyspora spinosa 
(WP_010694383)] (643, 71) 
Polyketide synthase 
[Saccharopolyspora erythraea 
(WP_011873765)] (533, 61) 
- 
SA24 Nonribosomal peptide 
synthetase [Kocuria 
rhizophila (WP_019309050)] 
(592, 73) 
- - 
SA25 Amino acid adenylation 
domain-containing protein 
[Salinispora arenicola 
(YP_001539321)] (453, 68) 
Rifamycin polyketide synthase 
[Salinispora arenicola 
(WP_020217874)] (578, 71) 
Ketosynthase, partial 
[Salinispora arenicola 
AFO70123] (548, 63) 
2.3. Anti-Infective Screening 
Twenty-five actinomycete isolates were fermented in the medium, from which they were originally 
isolated, and ethyl acetate and methanol were used for extraction of secondary metabolites. The ethyl 
acetate and methanolic extracts were then screened against Bacillus sp. P25, Escherichia coli K12, 
Fusarium sp. P21, Trypanosoma brucei TC 221, Leishmania major and NS3 protease of West Nile 
Virus (Table 3). Nine actinobacterial extracts were active against at least one test pathogen.  
No activities were documented against L. major. Two isolates were active against Bacillus sp. and  
E. coli K12 while antifungal activities were reported for six extracts and anti-trypanosomal activity 
was documented for five extracts. 
Two Micrococcus isolates were bioactive. Members of the genus Micrococcus were cultivated from 
diverse terrestrial and marine environments, however they are not well known for production of 
secondary metabolites. The antibiotic 2,4,4′-trichloro-2′-hydroxydiphenylether from sponge-associated 
Micrococcus luteus [48] and recently the thiazolyl peptide kocurin against methicillin-resistant 
Staphylococcus aureus [49]. Although the two Micrococcus isolates SA1 and SA3 are phylogenetically 
related (identical 16S rRNA sequences, Figure 2), their ethyl acetate extracts exhibited different 
biological profiles. This means that 16S rRNA gene as phylogenetic marker alone was not sufficient to 
distinguish genomic differences between actinomycete isolates sharing identical 16S rRNA gene 
sequence homologies and display different biosynthetic gene expression that could result in the 
production of different natural products [50]. 
The ethyl acetate extracts of Salinispora sp. SA6 and SA22 were active against almost all test 
pathogens, except L. major. The obligate marine Salinispora strains are prolific producers of 
structurally diverse natural products such as salinosporamide A from S. tropica, a potent proteasome 
inhibitor that has reached phase I clinical trials as an anticancer agent [51]. Other examples of 
bioactive compounds from various Salinispora species include arenimycin, rifamycins [52], 
cyanosporaside A, [53] saliniketals A and B [54], salinipyrones, and pacificanones [55]. The results 
highlight the high chemical potential of Salinispora isolates. 
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Table 3. Bioactivity results of the actinomycete isolates. 
Isolate Code 
Inhibition Zone Diameter (mm) 
IC50  
(μg/mL, 72 h) 
Growth  
Inhibition (%) 
Bacillus 
sp. P25 
Escherichia 
coli K12 
Fusarium 
sp. P21 
Trypanosoma 
brucei TC 221 
West Nile 
Virus Protease 
Micrococcus sp. SA1E 8 12 - <10 - 
Micrococcus sp. SA3E - - 14 - - 
Salinispora sp. SA6E 20 7 22 <10 84 
Salinispora sp. SA22E 18 9 15 <10 79 
* Rhodococcus sp. SA9E - - 13 - - 
* Rhodococcus sp. SA12E - - 16 - 93 
Mycobacterium sp. SA11E 14 - - <10 - 
Saccharomonospora sp. SA21 E 10 12 - - - 
Saccharomonospora sp. SA23 E 11 13 17 <10 - 
* Putatively new species. 
Two extracts of the novel isolates Rhodococcus sp. SA9 and SA12 exhibited antifungal activity 
against Fusarium sp. P21 with Rhodococcus sp. SA12 showing additional activity against West Nile 
Virus NS3 protease. One isolate of the genus Mycobacterium showed activity against Bacillus sp. P25 
as well as Trypanosoma brucei TC 221. The ethyl acetate extract of Saccharomonospora sp. SA21 was 
active against Bacillus sp. P25 and Escherichia coli K12 while Saccharomonospora sp. SA23 showed 
more broad activities against Bacillus sp. P25, Escherichia coli K12, Fusarium sp. P21, and 
Trypanosoma brucei TC 221.West Nile Virus (WNV) is a zoonotic virus which is widespread and 
endemic in Africa, the Middle East and western Asia as well as other parts of the world including United 
States, Europe and Australia [56]. There are commercially available animal vaccines, however up to 
date, no vaccines or treatments have been approved for human WNV infections [57]. This illustrates 
the urgent need to develop effective vaccines and antiviral drugs to prevent WNV infection in humans. 
The WNV protease NS3 is a prime target for antiviral drugs and has become the focus of considerable 
research efforts [57,58]. Interestingly, three ethyl acetate extracts (SA 6E, 22E, 12E) showed activity 
against WNV protease NS3 in the present study. Bioactivities were documented for ethyl acetate, but 
not methanolic extracts, which was consistent with literature reports showing that the majority of 
microbial natural products are secreted into the medium [59,60]. 
3. Experimental Section  
3.1. Sponge Collection 
Ten sponge species (Amphimedon ochracea, Amphimedon aff. chloros, Acarnus wolffgangi, 
Chalinula sp., Crella cyathophora, Dactylospongia aff. elegans, Hyrtios erectus, Monanchora sp., 
Subera sp., Xestospongia aff. testudinaria) were collected by SCUBA diving at depths of 8–12 m in 
the Red Sea (Saudi Arabia, Thuwal, Fsar Reef, GPS: 22°23′ N; 39°03′ E) in June 2012. Taxonomic 
identification was performed by Nicole de Voogd (Naturalis Biodiversity Center, Leiden, The 
Netherlands). Sponges were transferred to plastic bags containing sea water and transported to the 
laboratory. Sponge specimens were rinsed in sterile sea water, cut into pieces of ca. 1 cm
3
, and 
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thoroughly homogenized in a sterile mortar with 10 volumes of sterile sea water. The supernatant was 
diluted in 10-fold series (10
−1
, 10
−2
, 10
−3
) and subsequently plated out on agar plates. Processing was 
equivalent among samples. 
3.2. Actinomycete Isolation and Identification 
M1, ISP medium 2 and Oligotrophic media (OLIGO) were used for actinomycete isolation as 
described previously [17]. All media were prepared in artificial sea water and were supplemented with 
cycloheximide (100 μg/mL) and nalidixic acid (25 μg/mL) to inhibit fungal growth and fast-growing 
Gram-negative bacteria, respectively. Actinomycetes were picked based on their morphological 
characteristics and re-streaked several times to obtain pure colonies. The isolates were maintained on 
plates for short-term storage and long-term strain collections were set up in medium supplemented 
with 30% glycerol at −80 °C. The isolates were abbreviated as “SA”. 
DNA was extracted using the AllPrep DNA/RNA mini kit (QIAGEN, Hilden, Germany) following 
manufacturer’s instructions. 16S rRNA gene amplification and sequencing were performed using the 
universal primers 27F and 1492R. Chimeric sequences were identified using the Pintail program [61]. 
Raw sequences were processed on the software Sequencher 4.9 (Genecodes Coorperation, Ann Arbor, 
MI, USA). After ambiguous bases were trimmed to a quality over 99%, forward and reverse strands 
were assembled into a contig with the length of more than 1300 bases. Nearest related and described 
sequences were searched with an initial Blast run against the NCBI database. The genus-level 
identification of all the sequences was done with RDP Classifier (-g 16srrna, -f allrank) [62] and 
validated with the SILVA Incremental Aligner (SINA) (search and classify option) [63]. An alignment 
was calculated again using the SINA web aligner (variability profile: bacteria). Gap-only position were 
removed with trimAL (-noallgaps) [64]. For phylogenetic tree construction, the best fitting model was 
estimated initially with Model Generator [65]. RAxML (-f a -m GTRGAMMA –x 12345 –p 12345 -# 
1000) [66] and the estimated model was used with 1000 bootstrap resamples to generate the 
maximum-likelihood tree. Visualization was done with TreeGraph2 [67]. The 16S rRNA gene 
sequences of the putatively novel isolates were deposited in GenBank under the accession numbers 
showed in parentheses: SA7 (KJ599861), SA8 (KJ599862), SA9 (KJ599863), SA11 (KJ599864), 
SA12 (KJ599865), SA13 (KJ599866), SA14 (KJ599867), and SA15 (KJ599868). 
3.3. PCR Screening of NRPS and PKS-II Gene Fragments 
Ketosynthase (KS) domains of type I polyketide synthase (PKS) gene were PCR amplified from 
genomic DNA using the primers K1F (5′-TSAAGTCSAACATCGGBCA-3′) and M6R  
(5′-CGCAGGTTSCSGTACCAGTA-3′). Type II PKS sequences were amplified using KSαF  
(5′-TSGRCTACRTCAACGCSCACGG-3′) and KSβR (5′-TACSAGTCSWTCGCCTGGTTC-3′).  
In order to target adenylation domains of NRPS genes, the degenerate PCR primers A3F  
(5′-GCSTACSYSATSTACACSTCSGG-3′) and A7R (5′-SASGTCVCCSGTSCGGTAS-3′) were  
used [68]. Sequences of the corresponding PCR products (KS domains, 1250–1400 bp; KSα and KSβ, 
800–900 bp; adenylation domains, 700 bp) [69] were compared with NRPS and PKS sequences in the 
NCBI database by using the Basic Local Alignment Search Tool X (BLASTX). 
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3.4. Secondary Metabolites Extraction and Bioactivity Testing 
Twenty-five strains were cultured in 500 mL Erlenmeyer flasks containing 250 mL of the 
appropriate cultivation medium for each isolate. The liquid cultures were grown for 7–10 days 
depending on their growth rate at 30 °C while shaking at 150 rpm. After cultivation and filtration,  
the supernatant was extracted with ethyl acetate (2 × 150 mL). The cells were macerated in 100 mL 
methanol and shaken for 3 h (150 rpm) then filtered. The extracts (ethyl acetate and methanol) were 
concentrated under vacuum and stored at 4 °C. 
3.4.1. Antibacterial and Antifungal Activities Testing 
Antimicrobial activity was tested using the standard disk diffusion assay against Bacillus sp. P25, 
Escherichia coli K12 and Fusarium sp. P21. Sterile filter disks (6 mm) loaded 3 times with the test 
extracts (25 μL, 20 mg/mL in methanol) were placed on agar plates that had been inoculated with the 
test microorganism. After incubation (24 h for Bacillus, Escherichia coli K12 and 48 h for Fusarium sp.) 
at 37 °C (Bacillus, Escherichia coli K12) and 30 °C (Fusarium sp.), the antimicrobial potential was 
quantitatively assessed as diameter of the inhibition zone (n = 2). 
3.4.2. Anti-Trypanosomal Activity 
Anti-trypanosomal activity was tested following the protocol of Huber and Koella [70].  
10
4
 trypanosomes per mL of Trypanosoma brucei brucei strain TC 221 were cultivated in Complete 
Baltz Medium. Trypanosomes were tested in 96-well plate chambers against different concentrations 
of test extracts at 10–200 μg/mL in 1% DMSO to a final volume of 200 μL. For controls, 1% DMSO 
as well as parasites without any test extracts were used simultaneously in each plate to show no effect 
of 1% DMSO. The plates were then incubated at 37 °C in an atmosphere of 5% CO2 for 24 h.  
After addition of 20 μL of Alamar Blue, the activity was measured after 48 and 72 h by light 
absorption using an MR 700 Microplate Reader (Dynatech Engineering Ltd., Willenhall, UK) at a 
wavelength of 550 nm with a reference wavelength of 650 nm. The IC50 values of the test extracts 
were quantified by linear interpolation of three independent measurements. 
3.4.3. Anti-Leishmanial Activity 
Anti-leishmanial activity was tested following the method of Ponte-Sucre et al. [71]. 10
7
 cells/mL 
Leishmania major promastigotes were incubated in complete medium for 24 h at 26 °C, 5% CO2, and 
95% humidity in the absence or presence of different concentrations of the test extracts (10–200 μg/mL, 
1% DMSO) to a final volume of 200 μL. Following the addition of Alamar Blue, the plates were incubated 
again and the optical densities were determined after 48 h with a Multiskan Ascent enzyme-linked 
immunosorbent assay (ELISA) reader (Multiskan Ascent, Thermo Electron Corporation, Dreieich, 
Germany). The effects of cell density, incubation time and the concentration of DMSO were examined 
in control experiments. The results were expressed in IC50 values by linear interpolation of three 
independent experiments. 
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3.4.4. West Nile Virus NS3 Protease Inhibition Assay 
The West Nile Virus NS3 protease inhibition assay was carried out using the commercial kit 
SensoLyte
®
 440 West Nile Virus Protease Assay Kit (AnaSep, San Jose, CA, USA) [58]. The 
quantification of protease activity was measured by using the fluorogenic peptide Pyr-RTKR-AMC 
which produces free AMC (7-amino-4-methylcoumarin) fluorophore upon NS3 protease cleavage. The 
extracts and protease solution were applied to 384-well plates and the total reaction mixture in each 
well was 40 μL. All extracts and controls were performed with three replicates and were generated 
according to the manufacturer’s instructions. Briefly, the test extracts and protease solution were 
mixed and incubated at 37 °C for 10 min before adding the fluorogenic substrate. After substrate 
addition, the reagents were completely mixed and incubated at 37 °C for one hour. The fluorescence 
intensities were measured using a SpectraMax
®
 Paradigm
®
 Multi-mode Microplate Detection Platform 
(Molecular Devices, Sunnyvale, CA, USA) at 354 nm (excitation) and 442 nm (emission). 
4. Conclusions 
Marine actinomycetes, such as those associated with marine sponges, are a rich source of bioactive 
natural products. In the present study, we isolated 47 actinomycetes representing 10 different genera 
and including eight putatively novel phylotypes. The isolates were obtained from sponges which were 
collected offshore Fsar reef, Saudi Arabia, a largely uncharted territory with respect to bioprospecting. 
Although 80% of actinomycetes contained at least one class of NRPS or PKS gene, antimicrobial 
activity was detected only for 36% of the isolates. This suggests that genomic mining is a worthwhile 
future endeavour. Bioactivities against bacteria, fungi, human parasites as well as West Nile Virus 
protease were reported for nine of the isolates. These results underscore the potential of Red Sea 
sponges as a source of novel actinomycetes with underexplored potential for drug discovery.  
The combination of PCR-based screening, phylogenetic analysis as well as bioactivity assays is  
a useful strategy to prioritize actinomycetes for further bioassay-guided isolation work. 
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